Latest ArticlesTo explore the effect of atosiban in the treatment of premature rupture of membranes in threatened preterm birth and its influence on placental blood perfusion and maternal and infant outcomes.
A total of 103 patients with premature rupture of membranes in threatened preterm birth in our hospital from September 2022 to August 2024 were selected and randomly divided into the study group (n=52, treated with atosiban) and the control group (n=51, treated with ritodrine hydrochloride). The clinical efficacy, placental blood perfusion, maternal and infant outcomes, symptom disappearance time, pregnancy prolongation time and the occurrence of adverse reactions were compared between the two groups.
After treatment, there was a significant difference in the total effective rate between the two groups (92.31% vs. 78.43%, P<0.05). The vascularization-blood flow index, flow index, placental vascularization index, neonatal asphyxia, fetal distress, amniotic fluid fecal contamination, incidence of maternal and infant adverse outcomes, and symptom disappearance time in the study group were all lower than those in the control group (P<0.05). The gestation time of the study group was longer than that of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05).
The application of atosiban in premature rupture of membranes in threatened preterm birth has a better effect. It can assist in stabilizing placental blood perfusion, improve maternal and infant outcomes, and enhance pregnancy safety.
To explore the effect of bivalirudin combined with alprostadil on myocardial blood perfusion, hematological parameters and prognosis in patients with acute ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
A total of 294 patients with acute STEMI admitted to our hospital from January 2021 to November 2024 were selected and divided into control group A (treated with bivalirudin), control group B (treated with heparin+alprostadil), and observation group (treated with bivalirudin+alprostadil) according to the random number table method, with 98 cases in each group. The thrombolysis in myocardial infarction test (TIMI) blood flow classification, corrected TIMI flow frame count (CTFC) after surgery, and the rate of no-reflow phenomenon were compared before and 10 minutes after the operation among the three groups. The levels of serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and hematological parameters in the three groups before and 3 days after the operation were compared. The occurrence of major adverse cardiac event (MACE) within 30 days after PCI in the three groups was statistically analyzed.
After the operation, the incidence of TIMI grade 3 in the observation group was higher than that in the control group (P<0.05), and the incidences of CTFC and the rate of no-reflow phenomenon were lower than those in the control group (P<0.05). Three days after the operation, the levels of serum IL-6, TNF-α, CRP, the ratio of neutrophil/lymphocyte, neutrophils, mean platelet volume, and the ratio of mean platelet volume/lymphocyte in the three groups were lower than those before the operation, while lymphocytes were higher than those before the operation (P<0.05), and (P<0.05). At 30 days after the operation, the incidence of MACE in the observation group was lower than that in the control group (P<0.05).
Bivalirudin combined with alprostadil can reduce the inflammatory response in patients with acute STEMI undergoing PCI, improve myocardial blood perfusion, and reduce the occurrence of postoperative MACE.
To explore the clinical efficacy of modified Shenling Baizhu powder combined with mesalazine in the treatment of mild to moderate ulcerative colitis (UC) with spleen deficiency and dampness accumulation syndrome.
A total of 70 patients with mild to moderate UC with spleen deficiency and dampness accumulation syndrome admitted to the outpatient and ward of the department of spleen and stomach diseases of Jiangyin Hospital of Traditional Chinese Medicine and Jiangsu Province Hospital of Traditional Chinese Medicine from October 2023 to December 2024 were selected and divided into control group and treatment group according to the random number table method, with 35 cases in each group. The control group was treated with mesalazine, while the treatment group was treated with the modified formula of Shenling Baizhu Powder in addition to the treatment of control group. Both groups were treated for 24 weeks. The total effective rate, symptom score, colonoscopy mucosal lesion scores, and iron death related factors were compared between the two groups.
The total effective rate of the treatment group was better than that of the control group (94.29% vs. 82.86%, P<0.05). After treatment, the average symptom scores, colonic mucosal lesion scores and serum ferrous ion of the two groups decreased significantly (P<0.05). The levels of serum superoxide dismutase, glutathione and glutathione peroxidase 4 increased significantly (P<0.05). The improvement of diarrhea, abdominal distension, abdominal pain, limb drowsiness and anorexia in the treatment group were better than those in the control group (P<0.05). There was no statistically significant difference in the improvement of purulent bloody stool and colonic mucosal lesions between the two groups (P>0.05). No significant adverse reactions were observed in the two groups during treatment.
The modified Shenling Baizhu powder has a remarkable therapeutic effect on patients with mild to moderate UC with spleen deficiency and dampness accumulation syndrome, and it has good safety and high clinical application value.
To explore the efficacy and safety of Bawei Yijing capsules combined with western medicine in the treatment of systemic sclerosis (SSc) of Yang deficiency and cold coagulation type, as well as its influence on the levels of T lymphocyte subsets.
A total of 112 patients with SSc admitted to our hospital from November 2020 to October 2022 were selected and randomly divided into the conventional group and the combined group, with 56 cases in each group. The conventional group received basic western medical treatment, while the combined group was treated with Bawei Yijing capsules on the basis of the conventional group. Both groups were treated for 12 weeks continuously.The changes of skin hardness scores and the levels of T lymphocyte subsets before and after treatment were recorded in both groups, respectively. Meanwhile, the clinical efficacy and the occurrence of adverse reactions in the two groups were observed and compared.
After treatment, the total effective rate of the conventional group was lower than that of the combined group (75.00% vs. 94.64%, P<0.05). The skin hardness scores of both groups decreased compared with those before treatment (P<0.05), and the combined group showed a greater decrease (P<0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ in both groups increased compared with before, while the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level decreased compared with before (P<0.05). Moreover, the combined group showed greater increases in CD3+, CD4+, and CD4+/CD8+ levels (P<0.05), and greater decreases in the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level (P<0.05). There was no significant difference in the incidence of adverse reactions between the groups during the treatment period (12.50% vs. 10.71%, P>0.05).
Bawei Yijing capsules combined with western medicine in the treatment of SSc can significantly improve the clinical efficacy, effectively alleviate the condition of patients, regulate the levels of T lymphocyte subsets, and has better safety.
To investigate the efficacy of metformin combined with nateglinide in the treatment of type 2 diabetes mellitus (T2DM) complicated with moderate to severe non-alcoholic fatty liver disease (NAFLD) and its influence on liver fibrosis.
A total of 120 patients with T2DM combined with moderate to severe NAFLD in Linquan County People's Hospital from November 2021 to December 2024 were selected and randomly divided into the observation group (metformin combined with nateglinide) and the control group (nateglinide), with 60 cases in each group. The treatment course for both groups was 4 weeks. The clinical efficacy, liver fibrosis, blood lipid, liver fat content, CT liver-spleen density ratio, chemokine, nesfatin-1 level and the incidence of adverse reactions were compared between the two groups.
After treatment, the total effective rate of treatment in the observation group was higher than that in the control group (93.33% vs. 78.33%, P<0.05). The levels of laminin, hyaluronic acid, type Ⅳ collagen, type Ⅲprocollagen, total cholesterol, triglycerides, low-density lipoprotein cholesterol, chemokine, nesfatin-1 and liver fat content in both groups were decreased compared with those before (P<0.05), and the levels in the observation group were lower than those in the control group (P<0.05). The levels of high-density lipoprotein cholesterol and densities of liver and spleen on CT scans in both groups increased compared with before (P<0.05), and the levels in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (6.67% vs. 1.67%, P>0.05).
For patients with T2DM combined with moderate to severe NAFLD, metformin combined with nateglinide can effectively improve liver fibrosis without increasing the risk of adverse reactions.
Based on the published literature and the data from completed clinical trials, the meta-analysis method was used to systematically evaluate the efficacy and safety of tenofovir and entecavir in the treatment of patients with chronic hepatitis B (CHB) cirrhosis.
PubMed, Web of Science, Embase, Clinicaltrials.gov, Cochrane library, China Biomedical Literature Service System database, China National Knowledge Infrastructure and Wanfang database were comprehensively searched. The search period was from the establishment date of the database to May 2024. The research data of tenofovir and entecavir in the treatment of patients with CHB cirrhosis were collected. The Cochrane systematic review method was used to screen the literature, evaluate the quality of the included literature, and extract the included characteristic information for meta-analysis. The outcome indicators included the negative conversion rate of hepatitis B virus (HBV)-DNA, the normalization rate of glutamic-pyruvic transaminase (GPT), the cumulative incidence of hepatocellular carcinoma (HCC), the cumulative mortality rate and the changes in estimated glomerular filtration rate (eGFR).
A total of 18 articles were included, involving 13 251 patients. The results showed that at 24 and 48 weeks of treatment, compared with entecavir, the negative conversion rate of HBV-DNA in the tenofovir group[odds ratio (OR)=0.84, 95% confidence interval (CI): 0.65—1.08, P=0.17; OR=0.98, 95%CI: 0.28—3.51, P=0.98] and the normalization rate of GPT (OR=1.12, 95%CI: 0.55—2.28, P=0.76; OR=1.35, 95%CI: 0.77—2.36, P=0.29) basically equivalent; Tenofovir can significantly reduce the incidence of cumulative HCC in patients (OR=0.57, 95%CI: 0.42—0.77, P=0.0003), However, there were no significant differences in cumulative mortality (OR=0.89, 95%CI: 0.44—1.83, P=0.76)and the change of eGFR changes (standardized mean difference: -3.02, 95%CI: -18.46—12.42, P=0.70)between the two groups.
Tenofovir and entecavir are basically equivalent in the treatment of CHB cirrhosis patients in terms of HBV-DNA negative conversion rate, eGPT normalization rate, cumulative mortality rate and renal function damage, while the former can significantly reduce the incidence of HCC in patients.
Proteolysis-targeting chimera (PROTAC) is a new technology for targeting protein degradation that has received great attention in the biomedical science community. PROTAC molecules can quickly and efficiently deplete target proteins by inducing degradation of target proteins using the ubiquitin-protease system, and can bind to substrates again to achieve multiple ubiquitination reactions, optimizing the dose dependence and drug resistance of traditional small molecules to a certain extent. However, this unique chemical structure and mechanism of action also brings many challenges to its in vivo and in vitro pharmacokinetic studies, mainly including poor solubility, poor permeability, poor oral absorption, and low bioavailability. Starting from the analysis of the physicochemical properties of PROTAC molecules, this article analyzed the pharmacokinetic characteristics and summarized the bioanalysis methods of such drugs. It also discussed the challenges and prospects of PROTAC technology, providing a reference for innovative research and breakthroughs in the field of PROTAC drugs.
Fondaparinux is the first artificially synthesized selective factor Ⅹa inhibitor of pentose. Due to its strong anticoagulant activity and certain safety, it is widely used in clinical practice. Especially for patients with low-molecular-weight heparin intolerance during pregnancy or those with heparin-induced thrombocytopenia, fondaparinux has become the preferred anticoagulant therapeutic drug. Fondaparinux has certain application value in obstetric related diseases such as venous thromboembolism, recurrent miscarriage and fetal growth restriction by inhibiting the activity of factor Ⅹa and not reacting with platelets. This article reviewed the clinical application of fondaparinux in the treatment of obstetrical-related diseases for clinical reference.
To analyze the application status, development trend and existing problems of the Data Monitoring Committee (DMC) in the research and development of new anti-tumor drugs.
Clinical trials of anti-tumor drugs that were registered and met the conditions in the drug clinical trial registration and information disclosure platform from January 1, 2013 to April 24, 2024 were collected. Descriptive analysis methods were used to analyze the application of DMC in different trial characteristics (trial status, research center, research scope, and research stage, etc.).
A total of 5 320 valid trials were included. Among them, there were 1 018 trials (19.14%) that adopted DMC. The proportion of trials with DMC was relatively high in those that were actively suspended (28.04%) and actively terminated (22.05%). Among the types of drugs, the application rates of DMC in biological products (22.43%) and chemical drugs (16.39%) were higher than those in traditional Chinese medicine (8.16%). The application rate of DMC was higher in phase Ⅲ trials (56.46%) and multi-center trials (22.32%). In terms of indication sites, the application rate of DMC in clinical trials of new anti-tumor drugs for lung and mediastinum (31.41%) and urinary system (37.84%) was relatively high.
The application of DMC in clinical trials of new anti-tumor drugs in China is generally relatively low, but it is slightly higher in high-risk trials. It is recommended to enhance the awareness of the sponsors of setting DMC according to the characteristics of different clinical trials, form more perfect DMC guidelines, and give full play to the advantages of DMC in protecting clinical trials.